KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Deferred Taxes (2020 - 2025)

Boston Scientific's Deferred Taxes history spans 6 years, with the latest figure at -$32.0 million for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 68.0% year-over-year to -$32.0 million; the TTM value through Dec 2025 reached -$12.0 million, up 86.67%, while the annual FY2025 figure was -$12.0 million, 86.67% up from the prior year.
  • Deferred Taxes for Q4 2025 was -$32.0 million at Boston Scientific, down from $69.0 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $147.0 million in Q4 2023 and bottomed at -$100.0 million in Q4 2024.
  • The 5-year median for Deferred Taxes is -$10.5 million (2024), against an average of -$10.8 million.
  • The largest annual shift saw Deferred Taxes crashed 7400.0% in 2022 before it soared 2000.0% in 2023.
  • A 5-year view of Deferred Taxes shows it stood at -$75.0 million in 2021, then surged by 109.33% to $7.0 million in 2022, then skyrocketed by 2000.0% to $147.0 million in 2023, then tumbled by 168.03% to -$100.0 million in 2024, then surged by 68.0% to -$32.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Deferred Taxes are -$32.0 million (Q4 2025), $69.0 million (Q3 2025), and -$90.0 million (Q2 2025).